Addition of Immune Checkpoint Inhibitors to Chemotherapy Versus Chemotherapy Alone in First-Line Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis

The addition of immune checkpoint inhibitors to chemotherapy has been one of the main clinical research endeavors over the last few years in patients with metastatic triple-negative breast cancer. Recent randomized controlled trials have presented heterogeneous results that have elicited discussion in the oncology community. Here, the authors conducted a systematic review and meta-analysis to evaluate this strategy.